SOUTH SAN FRANCISCO, Calif., Aug. 9, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today reported financial results for the second quarter 2017, and provided an update on its business.
Business highlights include:
